NCT lookup
Pull any trial record directly from ClinicalTrials.gov.
Sponsor: Paris Translational Research Center for Organ Transplantation
Conditions: Rejection Acute Renal, Rejection Chronic Renal, Transplantation, Kidney Rejection Transplant
Interventions: Donor-derived cell-free DNA
Countries: United States, Belgium, Brazil, France, Germany, South Korea, Spain, Switzerland
This is a multinational, multi-center, observational cohort study. Kidney allograft rejection is poorly detected by standard-of-care biomarkers. Although dd-cfDNA has been associated with improved rejection detection when added to standard-of-care biomarkers and clinical parameters, little is known about its performance across Banff 2022 rejection phenotypes and injury patterns, in various clinical scenarios and populations, and when measured repeatedly over time.
Sex: ALL
Healthy volunteers: No
Study type: OBSERVATIONAL
Inclusion Criteria: * Recipients transplanted from a deceased or living donor * Kidney allograft biopsy concomitantly with dd-cfDNA measurement * Written informed consent at the time of transplantation for inclusion the center database Exclusion Criteria: * Combined organ transplantation * Pregnant women * Grafts from monozygotic twins * Recipient of a bone marrow transplant
- Los Angeles, California, United States
- Los Angeles, California, United States
- Los Angeles, California, United States
- Tampa, Florida, United States
- Atlanta, Georgia, United States
- St Louis, Missouri, United States
- St Louis, Missouri, United States
- New York, New York, United States
- Cleveland, Ohio, United States
- Dallas, Texas, United States
- Murray, Utah, United States
- Salt Lake City, Utah, United States
- Richmond, Virginia, United States
- Madison, Wisconsin, United States
- Leuven, Belgium
- São Paulo, Brazil
- Paris, France
- Paris, France
- Paris, France
- Paris, France
- Toulouse, France
- Berlin, Germany
- Seoul, South Korea
- Barcelona, Spain
- Geneva, Switzerland